AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (cancel)

2. (currently amended) A method for determining ~~which~~ whether a beagle dog is an extensive metabolizer or a poor metabolizer in the rate of drug metabolism, said method comprising:

preparing a nucleic acid sample from a beagle dog, ~~and~~

~~determining~~ analyzing a base corresponding to a base at position 1117 of a ~~canine~~ beagle CYP1A2 gene, ~~(at position 1179 of the nucleotide sequence of SEQ ID NO: 22)~~.

determining the CYP1A2 genotype at the base corresponding to a base at position 1117 of the beagle CYP1A2 gene, and

determining whether the beagle dog is an extensive metabolizer or a poor metabolizer according to the CYP1A2 genotype.

3. (currently amended) A method for selecting a beagle dog used in a medicament test, comprising

determining ~~which~~ whether a beagle dog is an extensive metabolizer or a poor metabolizer in the rate of drug metabolism by the method according to claim 2, and

selecting a beagle dog that is an extensive metabolizer or a beagle that is a poor metabolizer.

4. (currently amended) A method for assaying a pharmacological effect and/or toxicity of a test drug, comprising

administering a test drug to an extensive metabolizer group or a poor metabolizer group

selected by the method according to claim 3, and

assaying a pharmacological effect and/or toxicity of the test drug.

5. (withdrawn) A single stranded DNA consisting of 15 to 30 nucleotides, which hybridizes to a

sense strand or an antisense strand of a canine CYP1A2 gene having the nucleotide sequence of

SEQ ID NO: 1 or the nucleotide sequence consisting of nucleotides 63-1601 of SEQ ID NO: 22,

or a genetic polymorphism thereof under stringent conditions, and selected from the group

consisting of:

> (1) a single stranded DNA consisting of 15 to 30 nucleotides, wherein a base
>
> corresponding to a base at position 405 of the nucleotide sequence of SEQ ID NO: 1 or at
>
> position 1179 of the nucleotide sequence of SEQ ID NO: 22 is contained, and the
>
> corresponding base is C;
>
> (2) a single stranded DNA consisting of 15 to 30 nucleotides, wherein a base
>
> corresponding to a base at position 405 of the nucleotide sequence of SEQ ID NO: 1 or at
>
> position 1179 of the nucleotide sequence of SEQ ID NO: 22 is contained, and the
>
> corresponding base is T; and
>
> (3) a single stranded DNA consisting of 15 to 30 nucleotides, which is a strand
>
> complementary to the single stranded DNA (1) or (2).

6. (withdrawn) The single stranded DNA according to claim 5, consisting of the nucleotide

sequence of SEQ ID NO: 14 or 16.

7. (withdrawn) An agent for diagnosing a polymorphism in metabolic activity of a drug which is a substrate specific to canine CYP1A2, said agent comprising as an active ingredient a reagent for detecting a base corresponding to a base at position 1117 of a canine CYP1A2 gene (at position 1179 of the nucleotide sequence of SEQ ID NO: 22).

8. (new) The method according to claim 2, wherein a beagle dog with a C/C genotype or a C/T genotype is an extensive metabolizer and a beagle dog with a T/T genotype is a poor metabolizer.

9. (new) The method according to claim 3, wherein a beagle dog with a C/C genotype or a C/T genotype is selected as the extensive metabolizer.

10. (new) The method according to claim 9, wherein a beagle dog with the C/C genotype is selected.

11. (new) The method according to claim 3, wherein a beagle dog with a T/T genotype is selected as the poor metabolizer.

12. (new) A method for assaying a pharmacological effect and/or toxicity of a test drug, comprising

      administering a test drug to the beagle dog selected by the method according to claim 9, and

      assaying a pharmacological effect and/or toxicity of the test drug.

13. (new) A method for assaying a pharmacological effect and/or toxicity of a test drug, comprising

administering a test drug to the beagle dog selected by the method according to claim 10, and

assaying a pharmacological effect and/or toxicity of the test drug.

14. (new) A method for assaying a pharmacological effect and/or toxicity of a test drug, comprising

administering a test drug to the beagle dog selected by the method according to claim 11, and

assaying a pharmacological effect and/or toxicity of the test drug.